Journal
JOURNAL OF NEUROSCIENCE
Volume 28, Issue 13, Pages 3384-3391Publisher
SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.0185-08.2008
Keywords
HSP90; LRRK2; G2019S; Parkinson's disease; protein degradation; chaperone
Categories
Funding
- Intramural NIH HHS [Z01 AG000959-04, Z99 AG999999] Funding Source: Medline
- NIA NIH HHS [1R21AG028811, R21 AG028811] Funding Source: Medline
- NINDS NIH HHS [P50 NS038377] Funding Source: Medline
Ask authors/readers for more resources
Parkinson's disease (PD), a progressive neurodegenerative disease characterized by bradykinesia, rigidity, and resting tremor, is the most common neurodegenerative movement disorder. Although the majority of PD cases are sporadic, some are inherited, including those caused by leucine-rich repeat kinase 2 (LRRK2) mutations. The substitution of serine for glycine at position 2019 (G2019S) in the kinase domain of LRRK2 represents the most prevalent genetic mutation in both familial and apparently sporadic cases of PD. Because mutations in LRRK2 are likely associated with a toxic gain of function, destabilization of LRRK2 may be a novel way to limit its detrimental effects. Here we show that LRRK2 forms a complex with heat shock protein 90 (Hsp90) in vivo and that inhibition of Hsp90 disrupts the association of Hsp90 with LRRK2 and leads to proteasomal degradation of LRRK2. Hsp90 inhibitors may therefore limit the mutant LRRK2-elicited toxicity to neurons. As a proof of principle, we show that Hsp90 inhibitors rescue the axon growth retardation caused by overexpression of the LRRK2 G2019S mutation in neurons. Therefore, inhibition of LRRK2 kinase activity can be achieved by blocking Hsp90-mediated chaperone activity and Hsp90 inhibitors may serve as potential anti-PD drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available